These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 28554416)

  • 21. Current strategies in the treatment of Parkinson's disease and a personalized approach to management.
    Diaz NL; Waters CH
    Expert Rev Neurother; 2009 Dec; 9(12):1781-9. PubMed ID: 19951137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonmotor symptoms in essential tremor: Comparison with Parkinson's disease and normal control.
    Lee SM; Kim M; Lee HM; Kwon KY; Koh SB
    J Neurol Sci; 2015 Feb; 349(1-2):168-73. PubMed ID: 25641389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous dopaminergic delivery in Parkinson's disease.
    Antonini A; Ursino G; Calandrella D; Bernardi L; Plebani M
    J Neurol; 2010 Nov; 257(Suppl 2):S305-8. PubMed ID: 21080194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical management of advanced Parkinson's disease.
    Goudreau JL
    Clin Geriatr Med; 2006 Nov; 22(4):753-72, v. PubMed ID: 17000334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson's disease: Diagnosis and appreciation of comorbidities.
    Deeb W; Nozile-Firth K; Okun MS
    Handb Clin Neurol; 2019; 167():257-277. PubMed ID: 31753136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Pragmatic Approach to the Perioperative Management of Parkinson's Disease.
    Lenka A; Mittal SO; Lamotte G; Pagan FL
    Can J Neurol Sci; 2021 May; 48(3):299-307. PubMed ID: 32959743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.
    Faulkner MA
    Expert Opin Drug Saf; 2014 Aug; 13(8):1055-69. PubMed ID: 24962891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensory symptoms in Parkinson's disease: Clinical features, pathophysiology, and treatment.
    Zhu M; Li M; Ye D; Jiang W; Lei T; Shu K
    J Neurosci Res; 2016 Aug; 94(8):685-92. PubMed ID: 26948282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Device-Aided Treatment Strategies in Advanced Parkinson's Disease.
    Timpka J; Nitu B; Datieva V; Odin P; Antonini A
    Int Rev Neurobiol; 2017; 132():453-474. PubMed ID: 28554418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonmotor features of Parkinson's disease subtypes.
    Marras C; Chaudhuri KR
    Mov Disord; 2016 Aug; 31(8):1095-102. PubMed ID: 26861861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care.
    Taylor J; Anderson WS; Brandt J; Mari Z; Pontone GM
    Am J Geriatr Psychiatry; 2016 Dec; 24(12):1171-1180. PubMed ID: 27746069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
    Bachmann CG; Zapf A; Brunner E; Trenkwalder C
    Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.
    Chaudhuri KR; Schapira AH
    Lancet Neurol; 2009 May; 8(5):464-74. PubMed ID: 19375664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed.
    Titova N; Martinez-Martin P; Katunina E; Chaudhuri KR
    J Neural Transm (Vienna); 2017 Dec; 124(12):1529-1537. PubMed ID: 29116411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relevance of dopaminergic level in nocturnal disability in Parkinson's disease: implications of continuous dopaminergic stimulation at night to treat the symptoms.
    Stocchi F; Stirpe P
    J Neural Transm (Vienna); 2014 Aug; 121 Suppl 1():S79-83. PubMed ID: 24990308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonmotor symptom complex of Parkinson's disease--an under-recognized entity.
    Mehndiratta M; Garg RK; Pandey S
    J Assoc Physicians India; 2011 May; 59():302-8, 313. PubMed ID: 21751608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease.
    Chahine LM; Daley J; Horn S; Duda JE; Colcher A; Hurtig H; Cantor C; Dahodwala N
    Parkinsonism Relat Disord; 2013 Oct; 19(10):859-63. PubMed ID: 23751512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.